Anti-cancer API Brigatinib cas 1197953-54-0

$5.00

≥1 Bag/Bags

Min. Order:: 1 Bag/Bags

Min. Order:: 1 Bag/Bags

Transportation:: Ocean, Air

Port:: Shanghai

Quantity:

Your message must be between 20 to 2000 characters

Contact Now

Basic Info

Place of Origin:	Hebei,China
Productivity:	100kg/month
Supply Ability:	100kg/month
Payment Type:	L/C,T/T
Incoterm:	FOB,CFR,CIF
Certificate:	ISO9001
Transportation:	Ocean,Air
Port:	Shanghai

Product Description

Brigatinib potently inhibits the in vitro kinase activity of ALK (IC50, 0.6 nM) and all five mutant variants tested, including G1202R (IC50, 0.6-6.6 nM). Brigatinib demonstrates a high degree of selectivity, only inhibiting 11 additional native or mutant kinases with IC50 <10 nM. These include ROS1, FLT3, and mutant variants of FLT3 (D835Y) and EGFR (L858R; IC50, 1.5-2.1 nM). Brigatinib exhibits more modest activity against EGFR with a T790M resistance mutation (L858R/T790M), native EGFR, IGF1R, and INSR (IC50, 29-160 nM) and does not inhibit MET (IC50 >1000 nM). In cellular assays, brigatinib inhibits ALK and ROS1 with IC50s of 14 and 18 nM, respectively. Brigatinib inhibits FLT3 and IGF-1R with about 11-fold lower potency (IC50, 148-158 nM) and inhibits mutant variants of FLT3 and EGFR with 15- to 35-fold lower potency (IC50, 211-489 nM). Brigatinib inhibits cell growth with GI50 values ranging from 503 to 2,387 nM in three ALK-negative ALCL and NSCLC cell lines[1]. Brigatinib inhibits ALK activity and abrogates proliferation of ALK addicted neuroblastoma cell lines, with IC50 of 75.27 ± 8.89 nM. Brigatinib inhibits both the ALK-I1171N and the ALK-G1269A mutant receptors at 10 and 4 nM levels, respectively[3].

Send your message to this supplier

* From:
* To:

Ms. Lily
* Messages:

Enter between 20 to 4,000 characters.

Related Keywords

Anti-cancer API , Brigatinib , Cas 1197953-54-0